Bellevue Group AG Has $4.43 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Bellevue Group AG grew its stake in Johnson & Johnson (NYSE:JNJFree Report) by 23.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 28,280 shares of the company’s stock after purchasing an additional 5,457 shares during the quarter. Bellevue Group AG’s holdings in Johnson & Johnson were worth $4,433,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Keener Financial Planning LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $40,000. WFA Asset Management Corp increased its position in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $44,000. Disciplined Equity Management Inc. bought a new position in Johnson & Johnson during the fourth quarter worth about $45,000. Finally, Altshuler Shaham Ltd grew its stake in Johnson & Johnson by 37.8% in the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after acquiring an additional 87 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, May 6th. lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Monday. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from, the company has a consensus rating of “Hold” and an average target price of $174.07.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

NYSE:JNJ opened at $147.10 on Tuesday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm’s 50-day simple moving average is $149.06 and its 200 day simple moving average is $154.88. The firm has a market cap of $354.02 billion, a price-to-earnings ratio of 9.18, a P/E/G ratio of 2.45 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the company earned $2.68 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.